20
Jan
Glenmark Pharmaceuticals Ltd. (Glenmark), has launched the sacubitril + valsartan tabletsin India, for the treatment of heart failure. Marketed under the brand name ‘Sacu V™’, it must be taken twice daily under doctor’s prescription. Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). The use of sacubitril+valsartan has anestablished role in treatment of patients with heart failure with reduced ejection fraction (HFrEF) and has been endorsed by the latest heart failure treatment guidelines in Europe4 and the USA. On the occasion…
